347 related articles for article (PubMed ID: 34638613)
1. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma.
Lee SK; Lee SW; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638613
[TBL] [Abstract][Full Text] [Related]
2. Current status and perspectives of immune-based therapies for hepatocellular carcinoma.
Aerts M; Benteyn D; Van Vlierberghe H; Thielemans K; Reynaert H
World J Gastroenterol; 2016 Jan; 22(1):253-61. PubMed ID: 26755874
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
Shen KY; Zhu Y; Xie SZ; Qin LX
J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
[TBL] [Abstract][Full Text] [Related]
4. Immune-based therapies for hepatocellular carcinoma.
Pinato DJ; Guerra N; Fessas P; Murphy R; Mineo T; Mauri FA; Mukherjee SK; Thursz M; Wong CN; Sharma R; Rimassa L
Oncogene; 2020 Apr; 39(18):3620-3637. PubMed ID: 32157213
[TBL] [Abstract][Full Text] [Related]
5. Is the Rationale of Anatomical Liver Resection for Hepatocellular Carcinoma Universally Adoptable? A Hypothesis-Driven Review.
Lin YJ; Ho CM
Medicina (Kaunas); 2021 Feb; 57(2):. PubMed ID: 33540784
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.
Llovet JM; Pinyol R; Yarchoan M; Singal AG; Marron TU; Schwartz M; Pikarsky E; Kudo M; Finn RS
Nat Rev Clin Oncol; 2024 Apr; 21(4):294-311. PubMed ID: 38424197
[TBL] [Abstract][Full Text] [Related]
7. Transient Kupffer cell depletion and subsequent replacement by infiltrating monocyte-derived cells does not alter the induction or progression of hepatocellular carcinoma.
Vanderborght B; De Muynck K; Gijbels E; Lefere S; Scott CL; Guilliams M; Beschin A; Vinken M; Verhelst X; Geerts A; Van Vlierberghe H; Devisscher L
Int J Cancer; 2023 Jun; 152(12):2615-2628. PubMed ID: 36912275
[TBL] [Abstract][Full Text] [Related]
8. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma.
Zeng Z; Yang B; Liao ZY
Oncol Lett; 2020 Oct; 20(4):45. PubMed ID: 32802167
[TBL] [Abstract][Full Text] [Related]
9. Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software.
Ali E; Červenková L; Pálek R; Ambrozkiewicz F; Pavlov S; Ye W; Hošek P; Daum O; Liška V; Hemminki K; Trailin A
J Vis Exp; 2024 Apr; (206):. PubMed ID: 38682951
[TBL] [Abstract][Full Text] [Related]
10. Retreatment with immunotherapy in a patient with hepatocellular carcinoma who received immune checkpoint inhibitors after primary curative treatment: a case report.
Wang T; Tang F; Li F; Yin W; Liang J
Front Oncol; 2024; 14():1321195. PubMed ID: 38646435
[TBL] [Abstract][Full Text] [Related]
11. Anti-stromal nanotherapeutics for hepatocellular carcinoma.
Yu Z; Huang L; Guo J
J Control Release; 2024 Mar; 367():500-514. PubMed ID: 38278367
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges.
Zheng S; Chan SW; Liu F; Liu J; Chow PKH; Toh HC; Hong W
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672664
[TBL] [Abstract][Full Text] [Related]
13. The Current and Prospective Adjuvant Therapies for Hepatocellular Carcinoma.
Du JS; Hsu SH; Wang SN
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611100
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-guided fine-tuned microbiome potentiates anti-tumor immunity in HCC.
Liu T; Guo Y; Liao Y; Liu J
Front Immunol; 2023; 14():1333864. PubMed ID: 38169837
[TBL] [Abstract][Full Text] [Related]
15. Photothermal Fibrous Chitosan/Polydopamine Sponge for Intraoperative Hemostasis and Prevention of Tumor Recurrence in Hepatocellular Carcinoma Resection.
Mu L; Qi L; Long H; Huang J; Zhong Z; Shi X; Chen C; Ye Q
Adv Sci (Weinh); 2024 Jan; 11(3):e2304053. PubMed ID: 38029340
[TBL] [Abstract][Full Text] [Related]
16. Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma.
Ganne-Carrié N; Nault JC; Ziol M; N'Kontchou G; Nahon P; Grando V; Bourcier V; Barge S; Beaugrand M; Trinchet JC; Seror O
Hepat Oncol; 2014 Oct; 1(4):395-408. PubMed ID: 30190975
[TBL] [Abstract][Full Text] [Related]
17. Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.
Rimassa L; Reig M; Abbadessa G; Peck-Radosavljevic M; Harris W; Zagonel V; Pastorelli D; Rota Caremoli E; Porta C; Damjanov N; Patel H; Daniele B; Lamar M; Schwartz B; Goldberg T; Santoro A; Bruix J
World J Gastroenterol; 2017 Apr; 23(13):2448-2452. PubMed ID: 28428725
[TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary approach for hepatocellular carcinoma patients: current evidence and future perspectives.
Oh JH; Sinn DH
J Liver Cancer; 2024 Mar; 24(1):47-56. PubMed ID: 38527905
[TBL] [Abstract][Full Text] [Related]
19. Vitamin K and hepatocellular carcinoma: The basic and clinic.
Jinghe X; Mizuta T; Ozaki I
World J Clin Cases; 2015 Sep; 3(9):757-64. PubMed ID: 26380822
[TBL] [Abstract][Full Text] [Related]
20. Resected Tumor Outcome and Recurrence (RESTORE) Index for Hepatocellular Carcinoma Recurrence after Resection.
Hoffman D; Shui A; Gill R; Syed S; Mehta N
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
